Growth and puberty in a prospective cohort of patients with sickle-cell anaemia: an assessment over ten years abstract
DOI:
https://doi.org/10.7322/jhgd.127681Palavras-chave:
sickle-cell anaemia, prospective cohort, growth, puberty.Resumo
Introduction: Hereditary haemoglobinopathies are the most common group of monogenic hereditary diseases in the world. Erythrocytes in sickle form, cellular expression of polymerization of deoxygenated HbS, cause intermittent vascular obstruction, leading to tissue ischaemia and consequent chronic damage in organs and endocrine glands. Objective: The evaluation of the growth pattern and pubertal development of a group of patients with sickle-cell anaemia (SCA) from childhood to adulthood. Methods: Thirty patients with SCA between the ages of 10 and 23 years were evaluated in a prospective longitudinal study at three points in time (Te1: 2005; Te2: 2010 and Te3: 2015) and compared with controls. Anthropometric, pubertal and hormonal evaluations were carried out. Age- and gender-specific Z-scores for weight, height and BMI (body mass index) were calculated according to the reference growth standards. Results: Thirty patients with SCA (mean age = 13.93 years) were evaluated at Te1 and 26 patients (mean age = 25.08 years) at Te3. The SCA group lower showed Z-scores for weight (p = 0.0002), height (p = 0.0184) and BMI (p = 0.0011) than the control group at Te1. At Te3, there was no difference in height, but weight (p = <0.0001) and BMI (p = <0.0001) were lower in the SCA group. Men showed greater weight commitment than women at the three study times (Te1: p = 0.0340, Te2: p = 0.0426 and Te3: p = 0.0387) and lower BMI in Te3 (p = 0.0155) in the SCA group. There was a significant increase in weight when comparing Te1 with Te3 (p = 0.0009) and in height when comparing Te1 with Te2 (p = 0.0292) and with Te3 (p = 0.0003) in the SCA group. There was a significant increase in weight when comparing Te1 and Te3 (p = 0.0009) and in height when comparing Te1 and Te2 (p = 0.0292) and Te3 (p = 0.0003) in the SCA group. At Te1, 14 cases and 2 controls were prepubertal. Bone age was delayed in 12 patients. Age at menarche was delayed and lower in the SCA group (mean = 15 years). Five patients had gestated, but no patient had experienced fatherhood. At Te1, TSH levels were higher (p = 0.0080) and T3 levels were lower (p = 0.0020) in the SCA group. At Te3, LH and FSH levels were higher in men with SCA (p = 0.0014; p; 0.0002). IGF-I levels were lower in cases both at Te1 (p = 0.0002) and at Te3 (p = 0.0032). Conclusions: Patients with SCA showed growth impairment and pubertal delay compared with healthy controls. However, albeit belatedly, they reached normal sexual maturation and height in adulthood. Women with SCA showed no fertility problems. The findings highlight the need to investigate the intention of paternity and fertility among men with SCA.Downloads
Referências
Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010;115(22):4331–6. DOI: http://dx.doi.org/10.1182/blood-2010-01-251348
Ozen S, Unal S, Erçetin N, Taşdelen B. Frequency and risk factors of endocrine complications in Turkish children and adolescents with sickle cell anemia. Turkish J Haematol. 2013;30(1):25-31. DOI: http://dx.doi.org/10.4274/tjh.2012.0001
Al-Saqladi AW, Bin-Gadeen HA, Brabin BJ. Growth in children and adolescents with sickle cell disease in Yemen. Ann Trop Paediatr 2010;30(4):287-98. DOI: http://dx.doi.org/10.1179/146532810X12858955921113
Cipolotti R, Caskey MF, Franco RP, Mello EV, Dal Fabbro AL, Gurgel RQ, et al. Childhood and adolescentes growth of patient with sickle cell disease in Aracaju. Ann Trop Paediatr. 2000;20(2):109-13. DOI: http://dx.doi.org/10.1080/02724930050043407
Singhal A, Thomas P, Cook R, Wierenga K, Serjeant G. Delayed adolescent
growth in homozygous sickle cell disease. Arch Dis Child. 1994;71(5):404-8.
Serjeant GR, Singhal A, Hambleton IR. Sickle cell disease and age at menarche in Jamaican girls: observations from a cohort study. Arch Dis Child 2001;85(5):375-8.
Zago MA, Costa FF, Tone LG, Bottura C. Hereditary hemoglobin disorders in a Brazilian population. Hum Hered. 1983;33:125-9.
Zemel BS, Kawchak D a, Ohene-Frempong K, Schall JI, Stallings V a. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res. 2007;61(5):607-13. DOI: http://dx.doi.org/10.1203/pdr.0b013e318045bdca
Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC Growth Charts for the United States: Methods and Development. Vital Heal Stat. 2002; (246):1-190.
Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85(9):660-7.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291-303.
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13-23.
Greulich WW, Pyles SI. Radiographic atlas of skeletal development of the hand and wrist. 2. ed. Stanford: Stanford University Press; 1959; p. 255.
Smiley D, Dagogo-Jack S, Umpierrez G. Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab 2008;4(2):102-9. DOI: http://dx.doi.org/10.1038/ncpendmet0702
Ashcroft MT, Serjeant GR, Desai P. Height, weight and skeletal age of Jamaican and adolescentes with sickle cell disease. Arch Dis Child 1972;47(254):519-24.
Singhal A, Thomas P, Cook R, Wierenga K, Serjeant G. Delayed adolescent growth in homozygous sickle cell disease. Arch Dis Child. 1994;71(5):404-8.
Henderson RA, Saavedra JM, Dover GJ. Prevalence of impaired growth in children with homozygous sickle cell anemia. Am J Med Sci. 1994;30796):405-7. DOI: http://dx.doi.org/10.1097/00000441-199406000-00004
Zago MA, Kerbauy J, Souza HM, Figueiredo MS, Costa FF, Cruz SM, et al. Growth and sexual maturation of Brazilian patients with sickle cell diseases. Trop Geogr Med. 1992; 44(4):317-21.
Veríssimo MPA. Crescimento e desenvolvimento nas doenças falciformes. Rev Bras Hematol Hemoter. 2007;39(3):271-4. DOI: http://dx.doi.org/10.1590/S1516-84842007000300015
Collett-Solberg PF, Fleenor D, Schultz WH, Ware RE. Short stature in children with sickle cell anemia correlates with alterations in the IGF-I axis. J Pediatr Endocrinol Metab. 2007;20(2):211-8. DOI: http://dx.doi.org/10.1515/JPEM.2007.20.2.211
Soliman AT, El Banna N, Al Salmi I, De Silva V, Craig A, Asfour M. Growth hormone secretion and circulating insulin-like growth factor-I (IGF-I) and IGF binding protein-3 concentrations in children with sickle cell disease. Metabolism. 1997;46(11):1241-5. DOI: http://dx.doi.org/10.1016/S0026-0495(97)90224-9
Yamamoto H, Yuzuru K. Relationship between plasma insulin-like growth factor I (IGF-I) levels and body mass index (BMI) in adults. Endocr J. 1993;40(1):41-5. DOI: http://dx.doi.org/10.1507/endocrj.40.41
Taddesse A, Woldie IL, Khana P, Swerdlow PS, Chu J, Abrams J, et al. Hypogonadism in Patients with Sickle Cell Disease: Central or Peripheral? Acta haematologica 2012;128(2): 65-8. DOI: http://dx.doi.org/10.1159/000337344
Modebe O, Ezeh UO. Effect of age on testicular function in adult males with sickle cell anemia. Fertil Steril 1995;63(4):907-12. DOI: http://dx.doi.org/10.1016/S0015-0282(16)57500-1
Lee PA, Migeon CJ. Puberty in boys: correlation of plasma levels of gonadotropins (LH, FSH), androgens (testosterone, androstenedione, dehydroepiandrosterone and its sulfate), estrogens (estrone and estradiol) and progestins (progesterone and 17-hydroxyprogesterone). J Clin Endocrinol Metab. 1975;41(3):556-62. DOI: http://dx.doi.org/10.1210/jcem-41-3-556
Viana Junior JW, Felix WO, Cipolotti R. Regularidade de ciclos e padrão ovulatório em jovens portadoras de anemia falciforme. Rev Bras Ginecol Obstet. 2010;32(11):3-7. DOI: http://dx.doi.org/10.1590/S0100-72032010001100002
Osegbe DN, Akinyanju O, Amaku EO. Fertility in male with sickle cell disease. Lancet. 1981;2(8241):275-6. DOI: http://dx.doi.org/10.1016/S0140-6736(81)90525-0
Parshad O, Stevens MC, Hudson C, Rosenthal J, Melville GN, Dunn DT, et al. Abnormal thyroid hormone and thyrotropin levels in homozygous sickle cell disease. Clin Lab Haematol. 1989;1194):309-15. DOI: http://dx.doi.org/10.1111/j.1365-2257.1989.tb00228.x
Phillips G, Becker B, Keller VA. Hypothyroidism in adults with sickle-cell anemia. Am J Med. 1992;92(5):567-70. DOI: http://dx.doi.org/10.1016/0002-9343(92)90757-3
Downloads
Publicado
Edição
Seção
Licença
CODE OF CONDUCT FOR JOURNAL PUBLISHERS
Publishers who are Committee on Publication Ethics members and who support COPE membership for journal editors should:
- Follow this code, and encourage the editors they work with to follow the COPE Code of Conduct for Journal Edi- tors (http://publicationethics.org/files/u2/New_Code.pdf)
- Ensure the editors and journals they work with are aware of what their membership of COPE provides and en- tails
- Provide reasonable practical support to editors so that they can follow the COPE Code of Conduct for Journal Editors (http://publicationethics.org/files/u2/New_Code.pdf_)
Publishers should:
- Define the relationship between publisher, editor and other parties in a contract
- Respect privacy (for example, for research participants, for authors, for peer reviewers)
- Protect intellectual property and copyright
- Foster editorial independence
Publishers should work with journal editors to:
- Set journal policies appropriately and aim to meet those policies, particularly with respect to:
– Editorial independence
– Research ethics, including confidentiality, consent, and the special requirements for human and animal research
– Authorship
– Transparency and integrity (for example, conflicts of interest, research funding, reporting standards
– Peer review and the role of the editorial team beyond that of the journal editor
– Appeals and complaints
- Communicate journal policies (for example, to authors, readers, peer reviewers)
- Review journal policies periodically, particularly with respect to new recommendations from the COPE
- Code of Conduct for Editors and the COPE Best Practice Guidelines
- Maintain the integrity of the academic record
- Assist the parties (for example, institutions, grant funders, governing bodies) responsible for the investigation of suspected research and publication misconduct and, where possible, facilitate in the resolution of these cases
- Publish corrections, clarifications, and retractions
- Publish content on a timely basis